Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has shared an announcement.
CARsgen Therapeutics Holdings Limited has announced an update to its share repurchase plan, allowing the company to buy back up to 25,461,295 shares in the open market over the next 50 trading days. This move, funded by non-IPO raised funds, reflects the board’s belief that the current share price undervalues the company’s business prospects and demonstrates confidence in its long-term growth. Additionally, YIJIE Biotech Holding Limited, a substantial shareholder, has increased its stake in the company, indicating strong confidence in CARsgen’s potential for growth and investment value.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited is a biotechnology company specializing in the development of innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. The company is focused on advancing its proprietary technologies and expanding its market presence in the global biopharmaceutical industry.
Average Trading Volume: 2,137,706
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.94B
For detailed information about 2171 stock, go to TipRanks’ Stock Analysis page.